Citation

BibTex format

@article{Dowall:2016:10.3390/v8110277,
author = {Dowall, SD and Bewley, K and Watson, RJ and Vasan, SS and Ghosh, C and Konai, MM and Gausdal, G and Lorens, JB and Long, J and Barclay, W and Garcia-Dorival, I and Hiscox, J and Bosworth, A and Taylor, I and Easterbrook, L and Pitman, J and Summers, S and Chan-Pensley, J and Funnell, S and Vipond, J and Charlton, S and Haldar, J and Hewson, R and Carroll, MW},
doi = {10.3390/v8110277},
journal = {Viruses},
title = {Antiviral Screening of Multiple Compounds against Ebola Virus},
url = {http://dx.doi.org/10.3390/v8110277},
volume = {8},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been renewed efforts to search for effective antiviral countermeasures. A range of compounds currently available with broad antimicrobial activity have been tested for activity against EBOV. Using live EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds were selected on a rational basis because their mechanisms of action suggested that they had the potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some antiviral activity against EBOV in previous tests. Nine compounds caused no reduction in viral replication despite cells remaining healthy, so they were excluded from further analysis (zidovudine; didanosine; stavudine; abacavir sulphate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine). A second screen of the remaining compounds and the feasibility of appropriateness for in vivo testing removed six further compounds (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and Tasigna). The three most promising compounds (17-DMAG; BGB324; and NCK-8) were further screened for in vivo activity in the guinea pig model of EBOV disease. Two of the compounds, BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concentrations tested, which warrants further investigation. Further, these data add to the body of knowledge on the antiviral activities of multiple compounds against EBOV and indicate that the scientific community should invest more effort into the development of novel and specific antiviral compounds to treat Ebola virus disease.
AU  - Dowall,SD
AU  - Bewley,K
AU  - Watson,RJ
AU  - Vasan,SS
AU  - Ghosh,C
AU  - Konai,MM
AU  - Gausdal,G
AU  - Lorens,JB
AU  - Long,J
AU  - Barclay,W
AU  - Garcia-Dorival,I
AU  - Hiscox,J
AU  - Bosworth,A
AU  - Taylor,I
AU  - Easterbrook,L
AU  - Pitman,J
AU  - Summers,S
AU  - Chan-Pensley,J
AU  - Funnell,S
AU  - Vipond,J
AU  - Charlton,S
AU  - Haldar,J
AU  - Hewson,R
AU  - Carroll,MW
DO  - 10.3390/v8110277
PY  - 2016///
SN  - 1999-4915
TI  - Antiviral Screening of Multiple Compounds against Ebola Virus
T2  - Viruses
UR  - http://dx.doi.org/10.3390/v8110277
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000390109100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
VL  - 8
ER  -
Download